Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study
Wid M. Alyamani, Attiah Khobrani, Fawaz O. Alenazy, Yahya A. Alzahrani, Maan H. Harbi · 2026
Read Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study by Wid M. Alyamani, Attiah Khobrani, Fawaz O. Alenazy, Yahya A. Alzahrani, Maan H. Harbi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13616786.txt.
Description
Ibrutinib is a mainstay drug for B-cell blood cancers, but how it treats patients outside trials is unevenly documented. Alyamani and co-authors reviewed fifty-seven patients treated at a medical city in Makkah, Saudi Arabia, following them through the end of 2025. They logged every side effect, graded its severity, and looked for traits that predicted serious harm or stopping the drug for good.
Every patient had at least one side effect, and 71.9 percent had at least one severe one, most often low neutrophils and high blood pressure. More than four in five needed a dose change, and nearly thirty percent quit the drug entirely. Prior ischemic heart disease went with quitting, and weak kidney function went with severe toxicity. Side effect patterns also differed between the first ninety days and later treatment. The authors urge watchfulness across the whole course of therapy.
Catalog record
| CREATOR | Wid M. Alyamani, Attiah Khobrani, Fawaz O. Alenazy, Yahya A. Alzahrani, Maan H. Harbi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |